Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genetic risk marker for schizophrenia identified:

This article was originally published in Clinica

Executive Summary

An international research team has identified a major risk gene for schizophrenia after finding a highly significant association between two genetic markers on both sides of the neuregulin-1 gene and the development of the disease. The gene, which is located on chromosome 8, codes for brain growth factors, which are involved in the development of glial cells, memory function, motor neurones and cancer, reports Hans Moises of the University of Kiel, Germany. Some 2.5 million are affected by schizophrenia in the US alone.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT065970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel